ArticleMolecular and cellular biology1997
Synergy between the Mos/mitogen-activated protein kinase pathway and loss of p53 function in transformation and chromosome instability.
Article in Molecular and cellular biology, 1997. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 119 citations in OpenAlex.
- LRRC8A: A multifaceted regulator in cancer, neurological disorders, metabolic diseases and immune modulation.Genes & diseases · 2026Review
- Discovery and technical validation of high-performance methylated DNA markers for the detection of cervical lesions at risk of malignant progression in low- and middle-income countries.Clinical epigenetics · 2024Article
- A Genomics Resource for 12 Edible Seaweeds to Predict Seaweed-Secreted Peptides with Potential Anti-Cancer Function.Biology · 2022Article
- Scaffold Proteins in Gastrointestinal Tumors as a Shortcut to Oncoprotein Activation.Gastrointestinal tumors · 2017Review
- Loss of p53-mediated cell-cycle arrest, senescence and apoptosis promotes genomic instability and premature aging.Oncotarget · 2016Article
- Clinical observations on chemotherapy curable malignancies: unique genetic events, frozen development and enduring apoptotic potential.BMC cancer · 2015Article
- ASPP1 and ASPP2 bind active RAS, potentiate RAS signalling and enhance p53 activity in cancer cells.Cell death and differentiation · 2013Article
- A screen for selective killing of cells with chromosomal instability induced by a spindle checkpoint defect.PloS one · 2012Article
- Chromosomal instability confers intrinsic multidrug resistance.Cancer research · 2011Article
- Multipolar mitosis of tetraploid cells: inhibition by p53 and dependency on Mos.The EMBO journal · 2010Article
- Article
- Stem cells, senescence, neosis and self-renewal in cancer.Cancer cell international · 2006Article
- Activation of extracellular signal-regulated kinase (ERK) in G2 phase delays mitotic entry through p21CIP1.Cell proliferation · 2006Article
- Upregulation of meiosis-specific genes in lymphoma cell lines following genotoxic insult and induction of mitotic catastrophe.BMC cancer · 2006Article
- Human Immunodeficiency virus type 1 Nef potently induces apoptosis in primary human brain microvascular endothelial cells via the activation of caspases.Journal of virology · 2005Article
- Inactivation of E2F3 results in centrosome amplification.Cancer cell · 2003Article
- Chromosome instability in human lung cancers: possible underlying mechanisms and potential consequences in the pathogenesis.Oncogene · 2002Review
- Human immunodeficiency virus type 1 Nef binds to tumor suppressor p53 and protects cells against p53-mediated apoptosis.Journal of virology · 2002Article
- Cellular N-Ras promotes cell survival by downregulation of Jun N-terminal protein kinase and p38.Molecular and cellular biology · 2002Article
- Unwinding the loop of Bcl-2 phosphorylation.Leukemia · 2001Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Constitutive activation of mitogen-activated protein kinase (MAPK) is a property common to many oncoproteins, including Mos, Ras, and Raf, and is essential for their transforming activities. We have shown that high levels of expression of the Mos/MAPK pathway in Swiss 3T3 fibroblast cause cells in S phase to undergo apoptosis, while cells in G1 irreversibly growth arrest. Interestingly, cells in G2 and M phases also arrest at a G1-like checkpoint after proceeding through mitosis. These cells fail to undergo cytokinesis and are binucleated. Thus, constitutive overexpression of Mos and MAPK cannot be tolerated, and fibroblasts transformed by Mos express only low levels of the mos oncogene product. Here, we show that p53 plays a key role in preventing oncogene-mediated activation of MAPK. In the absence of p53 (p53-/-), the growth arrest normally observed in wild-type p53 (p53+/+) mouse embryo fibroblasts (MEFs) is markedly reduced. The mos transformation efficiency in p53-/- MEFs is two to three orders of magnitude higher than that in p53+/+ cells, and p53-/- cells tolerate > 10-fold higher levels of both Mos and activated MAPK. Moreover, we show that, like Mos, both v-ras and v-raf oncogene products induce apoptosis in p53+/+ MEFs. These oncogenes also display a high transforming activity in p53-/- MEFs, as does a gain-of-function MAPK kinase mutant (MEK*). Thus, the p53-dependent checkpoint pathway is responsive to oncogene-mediated MAPK activation in inducing irreversible G1 growth arrest and apoptosis. Moreover, we show that the chromosome instability induced by the loss of p53 is greatly enhanced by the constitutive activation of the Mos/MAPK pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.